Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News TC BioPharm (Holdings) plc TCBP

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:TCBP)

Fundamentals Snapshot (NDAQ:TCBP)

Opinion & Analysis (NDAQ:TCBP)

No current opinion is available.

Bullboard Posts (NDAQ:TCBP)

TCBP ....on watch after retracement

73 pesos
Iseneschal - May 26, 2022

$TCBP News Clips

Orphan drug status is a designation granted by the Federal Drug Administration for therapies targeting rare diseases. The status allows...
Desandan - March 17, 2022

$TCBP News clips

"This is another milestone achieved by TC BioPharm, further strengthening our leadership position in Gamma Delta therapies for...
Desandan - March 17, 2022

$TCBP News clips

 
Desandan - March 17, 2022

$TCBP News clips

EDINBURGH, Scotland, March 17, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company...
Desandan - March 17, 2022

$TCBP News clips

Dr. Michael Leek, Founder and Executive Chairman commented, "Apart from matched bone-marrow stem cell transplants, patients...
Desandan - March 16, 2022